Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Epidermolysis Bullosa Dystrophica: early-phase trial registry
2 of 4 indexed Epidermolysis Bullosa Dystrophica trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Epidermolysis Bullosa Dystrophica: 4 US clinical trials tracked, 2 recruiting.
Epidermolysis Bullosa Dystrophica is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Abeona Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition epidermolysis-bullosa-dystrophica
OPEN 2 | RECR 50% | LATE 0 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Epidermolysis Bullosa Dystrophica lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Epidermolysis Bullosa Dystrophica on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Epidermolysis Bullosa Dystrophica is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Stanford University
NCT01019148
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
Krystal Biotech
NCT06563414
Artificial Intelligence Patient App for RDEB SCCs
Northwestern University
NCT05843994
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics
NCT01263379
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Epidermolysis Bullosa Dystrophica records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Epidermolysis Bullosa Dystrophica trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Epidermolysis Bullosa Dystrophica page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Epidermolysis Bullosa Dystrophica trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Abeona Therapeutics sponsors the most Epidermolysis Bullosa Dystrophica trials on record, review their full trial history before evaluating a specific study. See Abeona Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epidermolysis Bullosa Dystrophica condition card totals 4 registered trials; most-linked intervention LZRSE-Col7A1 Engineered Autologous Epidermal Sheets; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.